MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US

Fri Feb 8, 2013 1:31am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130208:nHUGcVYY



MorphoSys AG / MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content
of this announcement. 


MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and
Trademark Office (USPTO) has granted the first patent covering the Company's latest antibody
platform Ylanthia, which became commercially available for existing and new partners in 2012.

"A growing patent portfolio on our new antibody platform Ylanthia is an important factor for a
successful partnering process in our core licensing markets, which we intend to intensify during
the course of 2013", commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

The new patent (US 8,367,586) covers the composition of MorphoSys's Ylanthia antibody library.
Ylanthia comprises more than 100 billion distinct, fully human antibodies, which makes it the
industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and
light chain framework combinations, which translates into unprecedented structural diversity. The
library's diversity is expected to result in antibodies against previously inaccessible target
molecules and unique epitope coverage.

Ylanthia's antibody frameworks were pre-selected for expression levels, stability and aggregation
behavior. A shift towards higher stability and stress tolerance will increase shelf life and serum
stability of resulting antibody products, making them more cost-effective to produce and
administer. A higher solubility in turn opens up the path for more convenient ways of
administration, to the benefit of patients. When needed, antibodies from the Ylanthia library are
optimized using MorphoSys's proprietary Slonomics technology. Slonomics enables optimization of
Ylanthia antibodies with unprecedented speed and flexibility.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical
industry. By successfully applying this and other patented technologies, MorphoSys has become a
leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare. 
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline
http://www.morphosys.com/pipeline  of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its
ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making
the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
http://www.morphosys.com/ .

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R) and
100 billion high potentials(R) are registered trademarks of MorphoSys AG. 

Slonomics(R) is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys
AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of
companies. The forward-looking statements contained herein represent the judgment of MorphoSys as
of the date of this release and involve risks and uncertainties. Should actual conditions differ
from the Company's assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as far as the wording
of the relevant press release is concerned.

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser 
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj 
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com mailto:investors@morphosys.com

Media Release (PDF) http://hugin.info/130295/R/1676426/546392.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


HUG#1676426



 --- End of Message --- 

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.